A final analysis of the Phase III TITAN study shows that Janssen’s Erleada (apalutamide), when added to androgen deprivation therapy, significantly improved overall survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with placebo.
The U.S. Food and Drug Administration approved a supplemental New Drug Application for Pfizer Inc. and Astellas Pharma Inc.’s Xtandi (enzalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer.
The U.S. Food and Drug Administration gave the green light to Johnson & Johnson’s Janssen for Erleada (apalutamide) as a treatment for metastatic castration-sensitive prostate cancer.
